Exposure to antiretroviral agents during pregnancy does not alter bone status in infants

Stefano Mora, Vania Giacomet, Alessandra Viganò, Laura Cafarelli, Sara Stucchi, Valentina Pivetti, Valeria Manfredini, Maria Puzzovio, Gianvincenzo Zuccotti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.

Original languageEnglish
Pages (from-to)255-258
Number of pages4
JournalBone
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Anti-Retroviral Agents
Bone and Bones
Pregnancy
HIV
Ultrasonography
Mothers
Tibia
Alkaline Phosphatase
Therapeutics
Parturition
Newborn Infant
Bone Resorption
Fetal Blood
Osteogenesis
Control Groups

Keywords

  • Antiviral treatment
  • Bone alkaline phosphatase
  • C-terminal telopeptide of type I collagen
  • HIV
  • Infants
  • Quantitative ultrasonography

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Mora, S., Giacomet, V., Viganò, A., Cafarelli, L., Stucchi, S., Pivetti, V., ... Zuccotti, G. (2012). Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone, 50(1), 255-258. https://doi.org/10.1016/j.bone.2011.10.030

Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. / Mora, Stefano; Giacomet, Vania; Viganò, Alessandra; Cafarelli, Laura; Stucchi, Sara; Pivetti, Valentina; Manfredini, Valeria; Puzzovio, Maria; Zuccotti, Gianvincenzo.

In: Bone, Vol. 50, No. 1, 01.2012, p. 255-258.

Research output: Contribution to journalArticle

Mora, S, Giacomet, V, Viganò, A, Cafarelli, L, Stucchi, S, Pivetti, V, Manfredini, V, Puzzovio, M & Zuccotti, G 2012, 'Exposure to antiretroviral agents during pregnancy does not alter bone status in infants', Bone, vol. 50, no. 1, pp. 255-258. https://doi.org/10.1016/j.bone.2011.10.030
Mora S, Giacomet V, Viganò A, Cafarelli L, Stucchi S, Pivetti V et al. Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. Bone. 2012 Jan;50(1):255-258. https://doi.org/10.1016/j.bone.2011.10.030
Mora, Stefano ; Giacomet, Vania ; Viganò, Alessandra ; Cafarelli, Laura ; Stucchi, Sara ; Pivetti, Valentina ; Manfredini, Valeria ; Puzzovio, Maria ; Zuccotti, Gianvincenzo. / Exposure to antiretroviral agents during pregnancy does not alter bone status in infants. In: Bone. 2012 ; Vol. 50, No. 1. pp. 255-258.
@article{7c52247610484507a5b484741dada675,
title = "Exposure to antiretroviral agents during pregnancy does not alter bone status in infants",
abstract = "The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.",
keywords = "Antiviral treatment, Bone alkaline phosphatase, C-terminal telopeptide of type I collagen, HIV, Infants, Quantitative ultrasonography",
author = "Stefano Mora and Vania Giacomet and Alessandra Vigan{\`o} and Laura Cafarelli and Sara Stucchi and Valentina Pivetti and Valeria Manfredini and Maria Puzzovio and Gianvincenzo Zuccotti",
year = "2012",
month = "1",
doi = "10.1016/j.bone.2011.10.030",
language = "English",
volume = "50",
pages = "255--258",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Exposure to antiretroviral agents during pregnancy does not alter bone status in infants

AU - Mora, Stefano

AU - Giacomet, Vania

AU - Viganò, Alessandra

AU - Cafarelli, Laura

AU - Stucchi, Sara

AU - Pivetti, Valentina

AU - Manfredini, Valeria

AU - Puzzovio, Maria

AU - Zuccotti, Gianvincenzo

PY - 2012/1

Y1 - 2012/1

N2 - The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.

AB - The use of combined antiretroviral agents during pregnancy is important to prevent mother-to-child transmission of human immunodeficiency virus (HIV). Antiretroviral treatment (ARV) is associated with reduced bone mass and altered bone metabolism in HIV-infected patients. There are no data regarding the effect of ARV exposure during pregnancy on newborns and infants. We therefore studied 38 subjects born from HIV-infected mothers, and we measured the speed-of-sound (SOS) at the tibia by quantitative ultrasonography (QUS) just after birth. QUS measurements at mid-tibia is easily performed in infants with the appropriate probe. Nevertheless, at this skeletal site only cortical bone is present, and therefore QUS measurements reflect the status of only one kind of bone tissue. We also measured bone alkaline phosphatase (BAP) and C-terminal telopeptide of type I collagen (CTX) in the cord blood as bone formation and resorption markers, respectively. SOS measurements were repeated at 4 and 12. months of age. As a control group we studied 94 subjects born from HIV-negative mothers. At birth the median (range) SOS of ARV-exposed neonates was 3006 (2870-3168) m/s, while that of control subjects was 3007 (2757-3311) m/s. The difference was not significant. BAP concentration of ARV-exposed was 103.6 (31.6-182.8) U/L, not different from that of control subjects (104.4 [43.2-227.2] U/L). CTX concentrations were 1.07 (0.26-2.8) ng/mL, and 1.38 (0.34-4.2) ng/mL in ARV-exposed and control subjects, respectively. SOS measurements at 4. months and 12. months of age were available for 17 ARV-exposed subjects and for 57 control subjects. SOS values changed significantly over time in both groups (F = 6.1; P.

KW - Antiviral treatment

KW - Bone alkaline phosphatase

KW - C-terminal telopeptide of type I collagen

KW - HIV

KW - Infants

KW - Quantitative ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=81255178826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81255178826&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2011.10.030

DO - 10.1016/j.bone.2011.10.030

M3 - Article

VL - 50

SP - 255

EP - 258

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -